| Matt Muramoto, DO | |
|
1001 Noble St, Fairbanks, AK 99701-4948 | |
| (907) 459-3500 | |
| (907) 459-3526 |
| Full Name | Matt Muramoto |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 14 Years |
| Location | 1001 Noble St, Fairbanks, Alaska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518287374 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 125231 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dcs Medical Pa | 0042507600 | 61 |
News Archive
In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).
Nexidia, a leading provider of customer interaction analytics solutions for business transformation, today announced that Blue Cross and Blue Shield of North Carolina (BCBSNC) has selected Nexidia's Enterprise Speech Intelligence (ESI) solution to support the company in determining enhancements to its service center operations.
A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.
In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.
› Verified 1 days ago
| Entity Name | Dcs Medical Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285082768 PECOS PAC ID: 0042507600 Enrollment ID: O20160926000390 |
News Archive
In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).
Nexidia, a leading provider of customer interaction analytics solutions for business transformation, today announced that Blue Cross and Blue Shield of North Carolina (BCBSNC) has selected Nexidia's Enterprise Speech Intelligence (ESI) solution to support the company in determining enhancements to its service center operations.
A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.
In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matt Muramoto, DO 1001 Noble St, Fairbanks, AK 99701-4948 Ph: (907) 459-3500 | Matt Muramoto, DO 1001 Noble St, Fairbanks, AK 99701-4948 Ph: (907) 459-3500 |
News Archive
In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).
Nexidia, a leading provider of customer interaction analytics solutions for business transformation, today announced that Blue Cross and Blue Shield of North Carolina (BCBSNC) has selected Nexidia's Enterprise Speech Intelligence (ESI) solution to support the company in determining enhancements to its service center operations.
A short paper that appeared recently on the preprint bioRxiv server pointed to a link between specific characteristics of anti-SARS-CoV-2 antibodies associated with the severity of COVID-19.
In the Sept. 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.
› Verified 1 days ago
Dr. Mark Andrew Clifford, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 122 1st Ave, Suite 600, Fairbanks, AK 99701 Phone: 907-750-4124 Fax: 808-433-1558 | |
Abigail J Klager, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1717 W Cowles St, Fairbanks, AK 99701 Phone: 907-451-6682 | |
Angela Lucien, PA-C Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1717 W Cowles St, Fairbanks, AK 99701 Phone: 907-452-8251 | |
Dr. Melinda F Evans, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1606 23rd Ave, Fairbanks, AK 99701 Phone: 907-455-4567 Fax: 907-458-1581 | |
Dr. Natalie Seibert Mayer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1867 Airport Way, Suite 120b, Fairbanks, AK 99701 Phone: 907-457-5050 Fax: 907-457-5034 | |
Dr. Peter John Dillon Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1001 Noble St, Fairbanks, AK 99701 Phone: 907-459-3500 Fax: 907-458-2628 | |
Dr. Russell Scott Pierce, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 751 Old Richardson Hwy Ste 200, Fairbanks, AK 99701 Phone: 907-457-9420 Fax: 907-457-1098 |